XML 40 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
DISCONTINUED OPERATIONS
 12 Months Ended
Dec. 31, 2017
Discontinued Operations and Disposal Groups [Abstract]  
DISCONTINUED OPERATIONS
NOTE 12 - DISCONTINUED OPERATIONS
 
As mentioned in note 2, the Company accounted for the termination of the Pfizer Agreement and the sale of the license as a discontinued operation, in accordance with ASU No. 2014-08.
 
The following summarizes financial information related to the Company’s discontinued operations, in the Company’s consolidated statements of operations:
 
 
 
2015
 
2016
 
(U.S. dollars in thousands)
 
 
 
 
 
 
 
REVENUES
 
$
48,674
 
$
209
 
COMPANY’S SHARE IN COLLABORATION AGREEMENT
 
 
5,048
 
 
 
 
COST OF REVENUES
 
 
(7,697)
 
 
(373)
 
GROSS PROFIT (LOSS)
 
 
46,025
 
 
(164)
 
RESEARCH AND DEVELOPMENT EXPENSES
 
 
(586)
 
 
 
 
Less –reimbursements
 
 
545
 
 
 
 
RESEARCH AND DEVELOPMENT EXPENSES, NET
 
 
(41)
 
 
 
 
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES
 
 
(564)
 
 
(25)
 
NET (LOSS) INCOME FOR THE YEAR FROM DISCONTINUED OPERATIONS
 
$
45,420
 
$
(189)
 
GAIN ON THE DISPOSAL
 
 
39,899
 
 
 
 
NET (LOSS) INCOME
 
$
85,319
 
$
(189)